Mind Medicine MindMed (MNMD)
(Delayed Data from NSDQ)
$8.11 USD
-0.27 (-3.22%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $8.12 +0.01 (0.12%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum C VGM
Price, Consensus and EPS Surprise
MNMD 8.11 -0.27(-3.22%)
Will MNMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MNMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MNMD
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?
MNMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why
MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag
What Makes Mind Medicine (MindMed) Inc. (MNMD) a New Buy Stock
Other News for MNMD
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Buy Rating Affirmed for Mind Medicine on Impressive MM120 Developments and Phase 3 Trial Prospects
MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
Mind Medicine appoints Stephanie Fagan Chief Corporate Affairs Officer
Mind Medicine transferred with Buy rating at Roth MKM